MetaCap

Integra LifeSciences Holdings Corporation (IART)

NASDAQ: IARTHealth CareMedical/Dental InstrumentsUSD

13.25-0.30 (-2.21%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IART stock chart

Technical analysis

Key statistics

All statistics
52-week range
8.70 – 20.49
Day range
13.16 – 13.79
Volume / Avg
826.61K / 1.05M
Beta
—

52-week range

$8.70$20.49

IART stock today

On Nov 20, IART ended the session at $13.25, shedding $0.30 (2.21%), versus the S&P 500's 3.70% decline. At this level, IART sits in the middle of its 52-week range of $8.70 to $20.49: 35.3% below the high, set on Jul 28, 2026 and 52.3% above the low. IART is up 6.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 10.0%.

Integra LifeSciences trades at 77.9x its trailing twelve-month earnings per share of $0.17. Its forward P/E of 5.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Integra LifeSciences

Company profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.

Industry
Medical/Dental Instruments
CEO
Dr. Stuart M. Essig Ph.D.
Headquarters
Princeton, NJ
Employees
4,427

Financial highlights

Full financials

In fiscal 2025, Integra LifeSciences generated $1.64 billion in revenue, up 1.5% from fiscal 2024, its 2nd consecutive year of revenue growth. Integra LifeSciences reported a net loss of $516.5 million, compared with a loss of $6.9 million a year earlier. Gross margin was 50.9% (down from 54.8%) and operating margin -30.2%.

Integra LifeSciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.64B$1.61B$1.54B$1.56B$1.54B
Growth+1.53%+4.47%-1.03%+0.99%+12.43%
Net income$-516.47M$-6.94M$67.74M$180.55M$169.07M
EPS (diluted)$-6.74$-0.09$0.84$2.16$1.98

Analyst forecast

Forecast

Consensus (12 analysts)

hold

Avg. price target

$15.67+18.26%

  • Strong buy 1
  • Buy 2
  • Hold 7
  • Sell 0
  • Strong sell 2

Target range

Low $13.00High $23.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 21, 2026
EPS actual vs est.
$0.59 vs $0.56
Surprise
+5.36%

IART news

All IART news

Integra LifeSciences peers

Health Care sector
IART peer companies
CompanyPrice% ChgMarket capCompare
IRMDiRadimed Corporation81.02-0.30%$1.04Bvs IART
ATECAlphatec Holdings Inc.6.68-3.19%$1.02Bvs IART
SGPSpyGlass Pharma Inc.30.43-1.14%$1.02Bvs IART
SIBNSI-BONE Inc.23.73-0.08%$1.07Bvs IART
DRTSAlpha Tau Medical Ltd.11.76+3.93%$1.09Bvs IART
AORTArtivion Inc.18.16-2.00%$886.02Mvs IART
TNDMTandem Diabetes Care Inc.17.46+3.93%$1.22Bvs IART
KIDSOrthoPediatrics Corp.31.74-2.37%$828.75Mvs IART

Indexes, lists and sector

Integra LifeSciences stock FAQ

What is Integra LifeSciences's stock price today?

IART last traded at $13.25 as of Nov 20, 4:00 PM EST, down 2.21% on the day. Prices are delayed at least 15 minutes.

Does Integra LifeSciences pay a dividend?

No. Integra LifeSciences does not currently pay a regular cash dividend.

What is IART's P/E ratio?

IART trades at a trailing P/E ratio of 77.94 and a forward P/E of 5.59.

Who is Integra LifeSciences's CEO?

Dr. Stuart M. Essig Ph.D. is the chief executive officer of Integra LifeSciences Holdings Corporation, which has about 4,427 employees.

Has IART ever split its stock?

Yes. The most recent IART stock split was a 2-for-1 split on Jan 4, 2017, one of 2 splits on record.

What is the IART 52-week high?

The 52-week high for IART is $20.49 and the 52-week low is $8.70. The stock is currently 35.3% below its high.

Compare IART